GLP-1 Market
LLY $1179.27 ▲ +0.8% NVO $38.64 ▲ +1.2% PFE $28.28 ▲ +1.7% VKTX $28.51 ▲ +2.8% KLRA $11.61 ▲ +16.1% GPCR $25.54 ▼ -0.5% RHHBY $54.09 ▲ +1.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Darifenacin Hydrobromide

Company
Oliver Blanchard
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for Darifenacin Hydrobromide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06249867

    A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

    Not yet reported Oliver Blanchard 60 participants Est. completion 2027-11 2 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT00127270

    Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

    Not yet reported Novartis 395 participants Est. completion 2006-02 67 sites Stand-alone
    Other conditions: Urinary Incontinence
    View official trial listing →
  • Completed NCT NCT00170755

    A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

    Not yet reported Novartis 718 participants Est. completion 2005-01 1 site Stand-alone
    Other conditions: Overactive Bladder Syndrome
    View official trial listing →
  • Completed NCT NCT00170768

    Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

    Not yet reported Novartis 150 participants Est. completion 2005-05 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT00171145

    A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

    Not yet reported Novartis 445 participants Est. completion 2004-12 1 site Stand-alone
    Other conditions: Overactive Bladder Syndrome
    View official trial listing →
  • Completed NCT NCT00171184

    Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

    Not yet reported Novartis 400 participants Est. completion 2006-06 1 site Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT00366002

    Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

    Not yet reported Novartis 500 participants Est. completion 2007-09 82 sites Stand-alone
    Other conditions: Overactive Bladder (OAB)
    View official trial listing →
  • Completed NCT NCT00413426

    Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects

    Not yet reported Novartis 28 participants Est. completion 2007-09 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00413790

    Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

    Not yet reported Novartis 162 participants Est. completion 2007-09 12 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00547378

    InSite for Over Active Bladder

    Not yet reported MedtronicNeuro 571 participants Est. completion 2016-08
    Other conditions: Urinary Incontinence, Urgency-frequency, Overactive Bladder
    View official trial listing →
  • Completed NCT NCT00703703

    Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

    Not yet reported Novartis 117 participants Est. completion 2008-10 21 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT00712322

    A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

    Not yet reported Warner Chilcott 35 participants Est. completion 2013-05-23 12 sites Stand-alone
    Other conditions: Neurogenic Detrusor Overactivity
    View official trial listing →
  • Completed NCT NCT00786448

    Post Marketing Surveillance Study on Emselex After Launch in Germany

    Bayer 5821 participants Est. completion 2006-02 1 site
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT00800462

    Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

    Not yet reported Toronto Rehabilitation Institute 23 participants Est. completion 2012-12 2 sites
    Other conditions: Spinal Cord Injury, Neurogenic Detrusor Overactivity
    View official trial listing →
  • Terminated NCT NCT00845338

    Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

    Not yet reported Bayer 7 participants Est. completion 2007-10 15 sites Stand-alone
    Other conditions: Multiple Sclerosis, Overactive Detrusor
    View official trial listing →
  • Completed NCT NCT00892450

    Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

    Not yet reported US Department of Veterans Affairs 12 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Parkinson's Disease, Overactive Bladder
    View official trial listing →
  • Completed NCT NCT00921245

    FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period

    Bayer 9 participants Est. completion 2009-02 1 site
    Other conditions: Overactive Bladder
    View official trial listing →
  • Withdrawn NCT NCT01018225

    Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

    Not yet reported Cognitive Research Corporation Est. completion 2010-07 Stand-alone
    Other conditions: Nocturia
    View official trial listing →
  • Terminated NCT NCT01189071

    Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

    Not yet reported University of Missouri-Columbia 3 participants Est. completion 2011-07 1 site
    Other conditions: Overactive Bladder, Renal Colic, Pain, Postoperative
    View official trial listing →
  • Status unknown NCT NCT01227811

    Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.

    Not yet reported Center for Clinical Pharmacology Research Bdbeq S.A. 24 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Bioequivalency
    View official trial listing →
  • Status unknown NCT NCT01229280

    Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.

    Not yet reported Center for Clinical Pharmacology Research Bdbeq S.A. 24 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Bioequivalency
    View official trial listing →
  • Completed NCT NCT02143570

    Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women

    Not yet reported Universidad de Valparaiso 80 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT02386072

    A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

    Astellas Scientific & Medical Affairs, Inc. 1524 participants Est. completion 2017-08-04 92 sites
    Other conditions: Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
    View official trial listing →
  • Completed NCT NCT03543566

    Bladder Antimuscarinic Medication and Accidental Bowel Leakage

    University of Alabama at Birmingham 32 participants Est. completion 2019-01-18 1 site
    Other conditions: Urinary Incontinence, Urge, Fecal Incontinence
    View official trial listing →
  • Completed NCT NCT03572231

    A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

    Astellas Pharma Singapore Pte. Ltd. 805 participants Est. completion 2020-03-30 15 sites
    Other conditions: Overactive Bladder (OAB)
    View official trial listing →
  • Completed NCT NCT03602508

    Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

    Astellas Pharma Singapore Pte. Ltd. 5589 participants Est. completion 2019-09-13 2 sites
    Other conditions: Overactive Bladder (OAB)
    View official trial listing →
  • Completed NCT NCT03662893

    Behavioural Therapy With Checklist for Overactive Bladder

    Not yet reported Ankara Training and Research Hospital 120 participants Est. completion 2018-04-15 1 site
    Other conditions: Overactive Bladder
    View official trial listing →
  • Completed NCT NCT06616675

    Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1

    Not yet reported Hospital Universitário Professor Edgard Santos 42 participants Est. completion 2023-12-20 1 site
    Other conditions: HTLV-1, Overactive Bladder Syndrome
    View official trial listing →
  • Completed NCT NCT07016451

    Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis

    Not yet reported Thanakrit Visuthikosol 25 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Radiation Cystitis
    View official trial listing →
  • Completed NCT NCT07206706

    Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS

    Not yet reported, Not yet reported Ain Shams University 150 participants Est. completion 2022-12-28 1 site Stand-alone
    Other conditions: Management of Ureteric Stent Related LUTS and Pain
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Darifenacin Hydrobromide, Darifenacin, Darifenacin 7.5 MG Extended Release Oral Tablet

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.